Skip navigation
Please use this identifier to cite or link to this item: https://repositorio.unb.br/handle/10482/44333
Files in This Item:
There are no files associated with this item.
Title: Alzheimer’s disease : innovative therapeutic approaches based on peptides and nanoparticles
Authors: Mota, Isabela Ferreira Lima
Lima, Larissa S. de
Santana, Bruna de M.
Gobbo, Giovanna de A. M.
Bicca, João V. M. L.
Azevedo, Juliana R. M.
Veras, Letícia G.
Taveira, Rodrigo de A. A.
Pinheiro, Gabriela B.
Mortari, Márcia Renata
metadata.dc.contributor.email: mailto:mmortari@unb.br
metadata.dc.identifier.orcid: https://orcid.org/0000-0002-9558-4787
https://orcid.org/0000-0002-6849-6001
Assunto:: Alzheimer, Doença de
Peptídeos
Venenos - proteínas - peptídeos
Nanopartículas
Issue Date: 21-May-2021
Publisher: SAGE Journals
Citation: MOTA, Isabela F. L. et al. Alzheimer’s disease: innovative therapeutic approaches based on peptides and nanoparticles. The Neuroscientist, maio 2021. DOI 10.1177/10738584211016409. Disponível em: https://journals.sagepub.com/doi/10.1177/10738584211016409. Acesso em: 27 jul. 2022.
Abstract: Alzheimer’s disease (AD) is the main cause of dementia in the world and its etiology is not yet fully understood. The pathology of AD is primarily characterized by intracellular neurofibrillary tangles and extracellular amyloid-β plaques. Unfortunately, few treatment options are available, and most treat symptoms, as is the case of acetylcholinesterase inhibitors (IAChE) and N-methyl-d-aspartate receptor antagonists. For more than 20 years pharmaceutical research has targeted the “amyloid cascade hypothesis,” but this has not produced meaningful results, leading researchers to focus now on other characteristics of the disease and on multitarget approaches. This review aims to evaluate some new treatments that are being developed and studied. Among these are new treatments based on peptides, which have high selectivity and low toxicity; however, these compounds have a short half-life and encounter challenges when crossing the blood-brain barrier. The present review discusses up-and-coming peptides tested as treatments and explores some nanotechnological strategies to overcome the downsides. These compounds are promising, as they not only act on the symptoms but also aim to prevent progressive neuronal loss.
DOI: https://doi.org/10.1177/10738584211016409
metadata.dc.relation.publisherversion: https://journals.sagepub.com/doi/10.1177/10738584211016409
Appears in Collections:CFS - Artigos publicados em periódicos

Show full item record Recommend this item " class="statisticsLink btn btn-primary" href="/handle/10482/44333/statistics">



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.